Definite and probable bioresorbable scaffold thrombosis in stable and ACS patients.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  EuroIntervention

• Publication date

  2015-07-22

• Fields of study

  Medicine, Engineering

• Identifiers
  DOI 10.4244/EIJY14M09_08PMID 25243382
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions (ABSORB II): an interim 1-year analysis of clinical and procedural secondary outcomes from a randomised controlled trial.

  2015cited by this paper
• Amsterdam Investigator-initiateD Absorb strategy all-comers trial (AIDA trial): a clinical evaluation comparing the efficacy and performance of ABSORB everolimus-eluting bioresorbable vascular scaffold strategy vs the XIENCE family (XIENCE PRIME or XIENCE Xpedition) everolimus-eluting coronary stent

  2014cited by this paper
• Fusion of optical coherence tomographic and angiographic data for more accurate evaluation of the endothelial shear stress patterns and neointimal distribution after bioresorbable scaffold implantation: comparison with intravascular ultrasound-derived reconstructions

  2014cited by this paper
• Lessons learned from acute and late scaffold failures in the ABSORB EXTEND trial.

  2014cited by this paper
• Intracoronary optical coherence tomography and histology of overlapping everolimus-eluting bioresorbable vascular scaffolds in a porcine coronary artery model: the potential implications for clinical practice.

  2013cited by this paper
• Examination of the in vivo mechanisms of late drug-eluting stent thrombosis: findings from optical coherence tomography and intravascular ultrasound imaging.

  2012cited by this paper
• Bioresorbable polymeric vascular scaffolds: a cautionary tale.

  2011cited by this paper
• Stent Thrombogenicity Early in High-Risk Interventional Settings Is Driven by Stent Design and Deployment and Protected by Polymer-Drug Coatings

  2011cited by this paper
• Optical coherence tomography (OCT) of overlapping bioresorbable scaffolds: from benchwork to clinical application.

  2011cited by this paper
• European Heart Journal

  2007cited by this paper

• Prognostic Impact of Calcified Plaque Morphology After Drug Eluting Stent Implantation　- An Optical Coherence Tomography Study.

  2021cites this paper
• Resultados clı́nicos tras el implante de armazones bioabsorbibles solapados en comparación con stents liberadores de everolimus de nueva generación

  2020influential citation
• Bioresorbable vascular scaffold versus Xience metallic stents: outcomes in the AIDA trial stratified by SYNTAX score.

  2020cites this paper
• Left Ventricular Hypertrophy Does Not Affect 1-Year Clinical Outcomes in Patients Undergoing Transcatheter Aortic Valve Replacement.

  2019cites this paper
• Safety and efficacy of the novel sirolimus‐eluting bioresorbable scaffold for the treatment of de novo coronary artery disease: One‐year results from a prospective patient‐level pooled analysis of NeoVas trials

  2019cites this paper
• Automated stent coverage analysis in intravascular OCT (IVOCT) image volumes using a support vector machine and mesh growing.

  2019cites this paper
• Everolimus-eluting bioresorbable vascular scaffolds for the left anterior descending coronary artery disease: 12-month follow up

  2018cites this paper
• Scaffold thrombosis following implantation of the ABSORB BVS in routine clinical practice: Insight into possible mechanisms from optical coherence tomography

  2018cites this paper
• Untangling the Diagnosis and Clinical Implications of Calcified Coronary Nodules.

  2017cites this paper
• Adverse outcomes following percutaneous transcatheter interventions

  2017cites this paper
• Systematic CT Methodology for the Evaluation of Subclinical Leaflet Thrombosis.

  2017cites this paper
• Bioresorbable Scaffolds versus Metallic Stents in Routine PCI

  2017cites this paper
• IVUS and OCT guided primary percutaneous coronary intervention for spontaneous coronary artery dissection with bioresorbable vascular scaffolds.

  2017cites this paper
• Mid-term and long-term safety and efficacy of bioresorbable vascular scaffolds versus metallic everolimus-eluting stents in coronary artery disease: A weighted meta-analysis of seven randomised controlled trials including 5577 patients

  2017cites this paper
• Antiplatelet Therapy After Implantation of Bioresorbable Vascular Scaffolds: A Review of the Published Data, Practical Recommendations, and Future Directions.

  2017cites this paper
• Two-year clinical outcomes of Absorb bioresorbable vascular scaffold implantation in complex coronary artery disease patients stratified by SYNTAX score and ABSORB II study enrolment criteria.

  2016cites this paper
• Bioabsorbable vascular scaffold overexpansion: insights from in vitro post-expansion experiments.

  2016cites this paper
• Long-Term Prognosis of Deferred Acute Coronary Syndrome Lesions Based on Nonischemic Fractional Flow Reserve.

  2016cites this paper
• Incidence, Predictors, and Mid-Term Outcomes of Possible Leaflet Thrombosis After TAVR.

  2016cites this paper
• Clinical Outcomes After Implantation of Overlapping Bioresorbable Scaffolds vs New Generation Everolimus Eluting Stents.

  2016cites this paper
• Drug-eluting stents to prevent stent thrombosis and restenosis

  2016cites this paper
• Are BVS suitable for ACS patients? Support from a large single center real live registry.

  2016cites this paper
• Bioresorbable Vascular Scaffolds in Routine Clinical Practice: Should We Wait Longer?

  2016cites this paper
• Scaffold Thrombosis After Percutaneous Coronary Intervention With ABSORB Bioresorbable Vascular Scaffold: A Systematic Review and Meta-Analysis.

  2016cites this paper
• Dual antiplatelet therapy, drug‐eluting stents and bioresorbable vascular scaffolds: Evolutionary perspectives

  2016cites this paper
• Mid- to Long-Term Clinical Outcomes of Patients Treated With the Everolimus-Eluting Bioresorbable Vascular Scaffold: The BVS Expand Registry.

  2016cites this paper
• Resultados clínicos tras el implante de armazones bioabsorbibles solapados en comparación con stents liberadores de everolimus de nueva generación

  2016cites this paper
• Biomechanical stress in coronary atherosclerosis: emerging insights from computational modelling

  2016cites this paper
• Three Cases of Early Lotus Valve Thrombosis.

  2016cites this paper
• Contemporary practice and technical aspects in coronary intervention with bioresorbable scaffolds: a European perspective.

  2015cites this paper
• Coronary Artery Vessel Healing Pattern, Short and Long Term, After Implantation of the Everolimus‐Eluting Bioresorbable Vascular Scaffold

  2015cites this paper
• What about the risk of thrombosis with bioresorbable scaffolds?

  2015cites this paper
• Everolimus-eluting stent platforms in percutaneous coronary intervention: comparative effectiveness and outcomes

  2015cites this paper
• Biodegradable vascular scaffold: is optimal expansion the key to minimising flow disturbances and risk of adverse events?

  2015cites this paper
• Absorb bioresorbable stents for the treatment of coronary artery disease

  2015cites this paper
• Differential aspects between cobalt-chromium everolimus drug-eluting stent and Absorb everolimus bioresorbable vascular scaffold: from bench to clinical use

  2015cites this paper
• Late Structural Discontinuity as a Possible Cause of Very Late Everolimus-Eluting Bioresorbable Scaffold Thrombosis.

  2015cites this paper
• Treatment of bioresorbable scaffold failure.

  2015cites this paper
• Mid- to Long-Term Clinical Outcomes of€Patients Treated With the Everolimus-Eluting Bioresorbable Vascular€Scaffold

  year unknowncites this paper